Deregulation of Cell Death in Cancer (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 226
Special Issue Editors
Interests: programmed cell death; apoptosis; leukaemia; epigenetic; acetylation; sirtuins
Special Issues, Collections and Topics in MDPI journals
Interests: leukaemia; epigenetic; personalized medicine; networking approaches
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the previous "Deregulation of Cell Death in Cancer" at https://www.mdpi.com/journal/cancers/special_issues/Deregulation_Cell_Death.
The correct balance between the production of “new” and the elimination of “old” cells is a central point of an important biological question under investigation, given that many pathologies arise through a disruption of homeostasis. Evading apoptosis is one of the well-identified hallmarks of cancer and is the principal characteristic of tumor cells, responsible for cancer initiation, progression, and metastasis processes.
Apoptosis is an extremely organized programmed process in which the coordination of specific well-described events, such as the disruption of cellular membranes, DNA fragmentation, cell shrinking, and removal of cellular debris, represent a fundamental condition to avoid immune response.
Different programmed cell deaths (PCDs) have been described and recently classified. The identification of the molecular mechanisms of PCD plays a pivotal role in our understanding of cancer. Considering that i) conventional diagnosis methods are not efficient for early-stage cancer detection, and ii) the silencing of the apoptotic responses might be contributing to the treatment resistance observed in many tumors, the study of proteins involved in PCD pathways and how it is possible to regulate, modulate, and restore PCD equilibrium might represent a useful approach in anticancer therapy.
This Special Issue aims to present the latest research underlining the relationship between cancer and PCD, new insights into the cellular mechanisms involved, drug discovery, and therapeutic-apoptosis-based strategies, which will allow us to gain a better understanding of the role of PCD in carcinogenesis.
Dr. Vincenzo Carafa
Prof. Dr. Lucia Altucci
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
